文献速递精神分裂症与精神病性障碍

氯氮平与其他口服二代抗精神病药在精神分裂症患者中的住院与全因停药关联:队列研究的系统综述与Meta分析

Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

尽管氯氮平组病情更重,其与显著降低的住院风险(RR 0.817)和全因停药(RR 0.732)相关,但体重、BMI和2型糖尿病风险显著增加。

要点

  • 氯氮平组病情更重(Hedges g 0.222),但住院风险显著低于NC-SGAs(RR 0.817)。
  • 氯氮平全因停药风险显著更低(RR 0.732,NNT 8),但2型糖尿病风险更高(RR 1.777)。
  • 氯氮平与总体症状和CGI严重度改善显著相关,但需监测体重和代谢指标。

核心结论

  • 在队列研究中,尽管接受氯氮平治疗的患者病情更重,氯氮平相比NC-SGAs仍与更好的关键疗效结局相关,但心脏代谢风险更高。

研究设计与样本

  • 系统检索PubMed、PsycINFO和CINAHL自建库至2018年12月17日无语言限制的文献,纳入比较氯氮平与NC-SGAs在精神分裂症或分裂情感障碍中有效性和/或安全性结局的非随机队列研究。
  • 采用随机效应模型计算未校正协变量和随访时间的风险比(RR)、需治疗人数/需伤害人数(NNT/NNH)以及标准化均数差(SMD)或均数差(MD)。

主要发现

  • 氯氮平与总体症状改善(SMD -0.302;95%CI -0.572至-0.032;P=0.03)和CGI严重度改善(SMD -1.182;95%CI -2.243至-0.122;P=0.03)显著相关。

临床怎么用

  • 在临床实践中,对于精神分裂症患者,氯氮平可能降低住院和全因停药风险,但需权衡代谢副作用。
  • 使用氯氮平时应监测体重、BMI和2型糖尿病风险,尤其对于已有代谢危险因素的患者。

局限性

  • 纳入研究为队列研究,非随机对照试验,可能存在混杂偏倚。
  • 风险比未校正协变量和随访时间。
  • 部分比较(如与特定NC-SGAs)的研究数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recent meta-analyses of randomized clinical trials (RCTs) comparing clozapine with nonclozapine second-generation antipsychotics (NC-SGAs) in schizophrenia have challenged clozapine's superiority in treatment-resistant patients. However, patients in RCTs are not necessarily generalizable to those in clinical practice. OBJECTIVE: To conduct a systematic review and meta-analysis to compare various outcomes of clozapine vs oral NC-SGAs in cohort studies. DATA SOURCES: Systematic literature search in PubMed, PsycINFO, and CINAHL without language restriction from database inception until December 17, 2018. STUDY SELECTION: Nonrandomized cohort studies reporting effectiveness and/or safety outcomes comparing clozapine with NC-SGAs in schizophrenia or schizoaffective disorder. DATA EXTRACTION AND SYNTHESIS: Independent investigators assessed studies and extracted data. Using a random-effects model, the study calculated risk ratio (RR) unadjusted for covariates and follow-up duration, number needed to treat/number needed to harm (NNT/NNH) for dichotomous data, and standardized mean difference (SMD) or mean difference (MD) for continuous data. MAIN OUTCOMES AND MEASURES: Coprimary outcomes were hospitalization and all-cause discontinuation. Secondary outcomes included all effectiveness and safety outcomes reported in at least 3 analyzable studies. RESULTS: Of 8446 hits, 68 articles from 63 individual cohort studies (n = 109 341) (60.3% male; mean [SD] age of 38.8 [6.5] years, illness duration of 11.0 [5.1] years, and study duration of 19.1 [23.3] months) were meta-analyzed. Compared with NC-SGAs, despite greater illness severity (17 studies [n = 38 766]; Hedges g, 0.222; 95% CI, 0.013-0.430; P = .04), clozapine was significantly associated with lower hospitalization risk (19 studies [n = 49 453]; RR, 0.817; 95% CI, 0.725-0.920; P = .001; NNT, 18; 95% CI, 12-40) and all-cause discontinuation (16 studies [n = 56 368]; RR, 0.732; 95% CI, 0.639-0.838; P < .001; NNT, 8; 95% CI, 6-12). Associations were statistically significant for comparisons with quetiapine fumarate and aripiprazole regarding hospitalization and all NC-SGAs, except aripiprazole, for all-cause discontinuation. Clozapine was also significantly associated with better outcomes regarding overall symptoms (SMD, -0.302; 95% CI, -0.572 to -0.032; P = .03) and Clinical Global Impressions scale severity (SMD, -1.182; 95% CI, -2.243 to -0.122; P = .03). Clozapine was significantly associated with increases in body weight (MD, 1.70; 95% CI, 0.31-3.08 kg; P = .02), body mass index (MD, 0.96; 95% CI, 0.24-1.68; P = .009), and type 2 diabetes (RR, 1.777; 95% CI, 1.229-2.570; P = .002; NNH, 27; 95% CI, 13-90). CONCLUSIONS AND RELEVANCE: In cohort studies, despite more severely ill patients being treated with clozapine, use of clozapine was associated with better key efficacy outcomes and higher cardiometabolic-related risk outcomes vs NC-SGAs.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Masuda T, Misawa F, Takase M, et al. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. JAMA Psychiatry. 2019. PMID: 31365048. doi:10.1001/jamapsychiatry.2019.1702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。